Become a fan of Slashdot on Facebook

 



Forgot your password?
typodupeerror
×
Science

America's First CRISPR Trial is Still Nearly 100% Effective 3 Years On (newatlas.com) 49

Incredible new data presented recently at the European Hematology Association Congress has revealed an experimental CRISPR gene editing therapy is both safe and effective up to three years after treatment. The follow-up results come from one of the longest-running human trials using CRISPR technology to treat a pair of rare genetic blood diseases. From a report: The first human trial in the United States to test CRISPR gene editing technology started back in 2019. The trial focused on two rare blood diseases: beta-thalassemia and sickle cell disease. The treatment involves first gathering stem cells from a patient's blood. Using CRISPR technology a single genetic change is made, designed to raise levels of fetal hemoglobin in red blood cells. The stem cells are then re-administered into the patients. Initial results were extraordinarily promising. The first two patients treated were essentially cured within months, but questions over long-term efficacy remained.

A follow-up announcement last year continued the impressive results with 22 patients treated and all demonstrating 100 percent success. Importantly, seven of those patients were 12 months past the initial treatment with no waning of efficacy. Now, a new data release is offering results from 75 patients treated with the groundbreaking CRISPR therapy, now dubbed exa-cel (exagamglogene autotemcel). Of those 75 patients treated, 44 were suffering transfusion-dependent beta thalassemia (TDT) and 31 had severe sickle cell disease (SCD). All but two of the 44 patients with TDT were essentially cured of their disease, needing no more blood transfusions. The two TDT patients still requiring blood transfusions had 75 percent and 89 percent reductions in transfusion volumes respectively. All 31 SCD patients were also free of disease symptoms at long-term follow-up.

This discussion has been archived. No new comments can be posted.

America's First CRISPR Trial is Still Nearly 100% Effective 3 Years On

Comments Filter:
  • But you can GMO my DNA..

  • "Incredible new data presented recently at the European Hematology Association Congress has revealed an experimental CRISPR gene editing therapy is both safe and effective up to three years after treatment".

    Well, that just leaves a few decades to go in the average life expectancy.

    • Except these people probably had a 2-year life expectancy due to their condition. Or worse. Most people allowed into experimental trials like this are in the “eh im gonna die next month anyway so what the hell” stage. Even if side effects shave decades off a full life expectancy, it’s a big advance and the patients are probably pretty damn grateful.
  • Killing the existing bone marrow with chemo is a risky procedure. Where's the viral gene editing cures?

    • by jbengt ( 874751 )

      Killing the existing bone marrow with chemo is a risky procedure.

      Is that what they did here? TFA doesn't say.
      I knew a woman who had an autologous bone marrow transplant, and it seemed extremely painful and dangerous. It wasn't a cure for any disease - it was a cure for the massive amount of chemo they gave to kill her stage 4 breast cancer. The idea was to harvest her bone marrow, give her enough chemo to kill her, or at least kill her bone marrow, filter out any cancerous cells from the harvested bone

  • Rare diseases with narrow causes offer the best shot at developing a tech with high confidence, but the results are the least immediately relevant.

    Humanity somehow cured widespread diseases repeatedly in the span of a couple of generations, but ever since then medical science has become an obscurantist shadow world of ambiguous treatments, politician's stat games, and (at least psychologically on the part of the lay public) a return to Early Modern skepticism at the basic competence of practitioners.

    T
    • by gtall ( 79522 )

      "Humanity somehow cured widespread diseases repeatedly in the span of a couple of generations,"

      so the low hanging fruit has already been picked...those naughty scientists.

      • Exactly, once vaccines became a thing it was pretty quick to adapt them to the most common viral diseases. Thing is they only work on those viral diseases.

        Antibiotics are the same thing, covered a huge amount of common illnesses, but they only apply to bacterial/fungal type infections.

        Now we are left with the tricky bastards. Cancer is just our own cells going haywire, much tougher of a problem to solve than an external threat.

      • "The low-hanging fruit was already picked" is the kind of explanation acceptable from an office manager explaining a dip in sales, not a phenomenon at the root of modern medical science. It also presupposes a full understanding of what remains to be known (i.e., the only way you can possibly define what "low-hanging fruit" is), which would be absurd.

        Two things seem to be at odds: Our level of biological knowledge is far beyond the early 20th century's, and yet the pace of progress in applying it appears
  • Why do these breakthroughs always seem to treat some rare condition instead of a common one?

"Once they go up, who cares where they come down? That's not my department." -- Werner von Braun

Working...